Mediastinoscopy: An obsolete procedure?  by Rusch, Valerie W.
General Thoracic Surgery Yasufuku et al
G
T
Sa lot by doing this study, because we get direct feedback from the
cytopathologist, and by doing that, we have been able to modify
how we sample our lymph nodes so that we can submit a better
sample.
Dr Cooper. Clearly, the significance that a person attaches to
the presence or absence of mediastinal lymph node involvement
will determine how vigorously he or she attempts to pursue the
goal that you achieved. What is your current policy on patients
with known or suspected lung cancer? How important is it to
you to obtain accurate mediastinal node sampling before thoracot-
omy, and what do you do with that information?
Dr Yasufuku. I think accurate mediastinal lymph node staging
is an important issue that affects patient outcome. In our current
practice, according to the results of our study, when patients
have a clinical N2 disease based on imaging, we would start out
the invasive staging with endobronchial ultrasound. We not only
sample 1 lymph node station, but, as I showed in this study, we typ-
ically do systematic lymph node sampling, not just going after
1 lymph node. Even if we do find metastasis in 1 lymph node,
we would also check the other mediastinal lymph node stations.
If we do confirm the disease and it is resectable, we would have
the patient undergo induction treatment. I think the beauty about
EBUS is that a redo EBUS is typically easier than a redo mediasti-
noscopy. So we can go back after induction treatment, follow-up
on these patients, and actually safely restage the patients. If neces-
sary, we can always do a mediastinoscopy as well.
Dr Cooper. Thank you, and that answered another question that
I had. Finally, do you obtain sufficient material for tumor markers,
which increasingly is important in directing the neoadjuvant
therapy of these patients?
Dr Yasufuku. Sometimes it may be a challenge, but if done in
the correct way, we have been able to obtain adequate samples for
molecular analysis, such as epidermal growth factor receptor mu-
tation analysis. Regular immunohistochemistry is done routinely
by the cytopathologist using the cell block, and the cytopathologist
is typically happy with what we submit.COMMEN
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1400 The Journal of Thoracic and Cardiovascular SurDr Frank Detterbeck (New Haven, Conn). Just a quick com-
ment. I think that EBUS is not EBUS is not EBUS, and mediasti-
noscopy is not mediastinoscopy. Certainly EBUS as you have done
it is different from what many people do; they quickly aspirate 1
node station and that is it, and the same with mediastinoscopy,
as Alex Little showed us in the United States in 2005, where
50% don’t even sample a single node. You have done a very sys-
tematic staging. Furthermore, video mediastinoscopy is better
than old-fashioned mediastinoscopy. It is important for us to con-
sider these results in this context as we figure out how to imple-
ment them more broadly.
Dr Bryan Meyers (St Louis, Mo). I enjoyed your article. It is
going to be an excellent contribution to the literature. The only
area where either of your treatment arms diverged from standard
clinical care was the use of a different needle at each site. Equip-
ment from Olympus was donated for the trial, and so it was okay.
We don’t have that same advantage during a case of routine clin-
ical care. How do you think that discrepancymight affect the inter-
pretation or generalizability of your results, and could you justify
why you chose to do that?
Dr Yasufuku. Thank you for raising an important issue. The
reason why we chose to use different needles was because we
wanted to eliminate contamination. I think we should ideally use
different needles for different lymph node stations, especially
when you do not have ROSE cytology where the cytopathologists
can tell you if the needle you used was positive for cancer or not.
We always start out our sampling from the N3 nodes and then work
our way to the N2 and N1 nodes. Needles cost approximately $80
to $100 each, but to prevent contamination and possible upstaging,
I think it is important to use different needles.
If you have ROSE cytologic evaluation and the lymph nodes
are found to be negative for malignancy, it may be possible to
use the same needle after washing the needle properly; however,
there have been no studies looking at the use of the same needle
for different lymph node stations and the impact on the final
diagnosis.TARYMediastinoscopy: An obsolete procedure?Valerie W. Rusch, MDFor approximately 50 years, mediastinoscopy has been
a pivotal part of the pretreatment staging of lung cancer.1
At one time, respected thoracic surgical groups in North
America and Europe considered mediastinoscopy manda-
tory before proceeding to resection of a non–small cell
lung cancer (NSCLC). However, during the past 30 years,
improvements in noninvasive imagingmodalities, first com-
puted tomography and then positron emission tomography,gery c December 2011
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Rusch Commentaryled tomore selective use ofmediastinoscopy focusing on pa-
tients with enlarged or hypermetabolic mediastinal lymph
nodes.2,3 During the past decade, the technology for
endobronchial ultrasound (EBUS) has become widely
available, and EBUS-guided transbronchial needle aspira-
tion (EBUS-TBNA) of hilar and mediastinal lymph nodes
has been shown to be feasible, safe, and accurate.4 Last
year, a prospective multicenter European trial reported ran-
domizing 241 patients withNSCLCwho had enlarged or hy-
permetabolic mediastinal lymph nodes to surgical
mediastinal staging (predominantly cervical mediastino-
scopy) or staging by endosonography, combined EBUS,
and esophageal ultrasound (EUS) plus surgical staging.
All patients found to have benign mediastinal lymph nodes
then underwent resection and mediastinal lymph node dis-
section.5 The combined strategyof endosonography and sur-
gical staging resulted in greater sensitivity for mediastinal
nodal metastases and fewer inappropriate thoracotomies
than surgical staging alone.
In this issue of the Journal, Yasufuku and colleagues6
from the University of Toronto report a prospective con-
trolled trial of EBUS-TBNA compared with mediastino-
scopy for the staging of NSCLC. During a 4-year period
from 2006 to 2010, 153 eligible patients with known or
suspected potentially resectable NSCLC underwent
EBUS-TBNA of the mediastinal lymph nodes followed
immediately by cervical mediastinoscopy with systematic
biopsies of subcarinal and bilateral paratracheal lymph
nodes. If frozen sections on the nodal biopsies were benign,
patients went on to surgical resection of the tumor. There
were no complications related to EBUS-TBNA, whereas
4 patients experienced minor complications from the
mediastinoscopy. There were no significant differences
between EBUS-TBNA andmediastinoscopy in determining
the true pathologic N stage, and the authors conclude
that EBUS-TBNA can replace mediastinoscopy for pre-
resection staging in patients with potentially resectable
NSCLC. Does this study establish a new standard of care
and render mediastinoscopy obsolete?
It is important to understand that this study sets the highest
possible bar both for the quality of mediastinoscopy and for
EBUS-TBNA. The University of Toronto group has a long
tradition of excellence in mediastinoscopy, and the system-
atic approach in this trial of biopsying all accessible lymph
node stations in the paratracheal and subcarinal regions
reflects that tradition. The leadership of Dr Yasufuku,
who is internationally recognized for helping to develop
EBUS-TBNA along with his colleagues,7,8 enabled all
the participating surgeons to perform this procedure
with consistent expertise. A minority of thoracic surgeons
worldwide are currently capable of performing both
mediastinoscopy and EBUS-TBNA at this level. An addi-
tional key technical aspect of EBUS-TBNA in this study is
the use of rapid on-site evaluation of needle aspirates byThe Journal of Thoracic and Cara cytopathologist or cytotechnologist. Such support frompa-
thologists is critical to determining the number of aspirates
required for successful diagnosis and can rightfully be con-
sidered standard care. A consistent approach to obtaining
a minimum of 3 aspirates and of using separate aspiration
needles for each lymph node station also optimized diagnos-
tic yield and prevented specimen cross-contamination.
Finally, as discussed by the authors, general anesthesia and
a laryngeal mask airway provide a quiet operative field
and maximize the ability to biopsy all paratracheal lymph
node stations. EBUS-TBNAalso has the advantage of allow-
ing biopsy of N1 lymph nodes (interlobar and peribronchial)
not accessible by mediastinoscopy and thus identifying pa-
tients with earlier stage diseasewhomay benefit from induc-
tion chemotherapy. Under these ideal conditions and in the
hands of surgeons expert in both procedures, it is certainly
reasonable to state that EBUS-TBNA can replace mediasti-
noscopy for staging potentially resectable NSCLC.
So what remains the role of mediastinoscopy? This pro-
cedure will likely still be necessary for diseases for which
a larger sample is needed for definitive diagnosis, including
various infectious or inflammatory conditions, small cell
lung cancer, and lymphoma. As the authors point out,
very small lymph nodes less than 5 mm are not reliably
biopsied by EBUS-TBNA. Although such nodes are usually
benign in patients with NSCLC, they may require mediasti-
noscopy for biopsy if other diseases are suspected. In addi-
tion, as molecular profiling becomes increasingly pivotal in
the management of thoracic malignancies, it will be impor-
tant to determine whether EBUS (or EUS)-TBNA samples
are sufficient for this purpose or whether mediastinoscopy is
still needed under some circumstances.
It is critical that thoracic surgeons develop expertise in
EBUS-TBNA and retain expertise in mediastinoscopy. As
suggested by the randomized European trial, expertise in
EUS-TBNA is also highly desirable because EUS provides
access to nodal stations (levels 5, 6, 8, and 9) that cannot be
reached by EBUS or mediastinoscopy. While EBUS-TBNA
is rapidly gaining popularity in the pulmonary medicine
community and EUS is frequently performed by gastroen-
terologists, thoracic surgeons are uniquely positioned to
offer patients the most efficient approach to diagnosis and
staging by performing any one or any combination of these
3 procedures in a single trip to the operating room. The
choice of procedure should be based on what offers the
patient the best disease management, not on the specialty
of the physician who happens to be seeing that patient.
Our thoracic surgical residency training programs need to
provide training in all of these techniques. Indeed, changes
in thoracic surgical index case requirements to include both
mediastinoscopy and EBUS are currently being considered
by the American Board of Thoracic Surgery and the Tho-
racic Surgery Residency Review Committee. Practicing
thoracic surgeons already proficient in mediastinoscopydiovascular Surgery c Volume 142, Number 6 1401
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Commentary Ruschshould move to gain experience in EBUS and EUS-TBNA
through hands-on skills courses. To disseminate expertise
in EBUS and EUS-TBNA, our thoracic surgical societies
should mount an intensive effort to provide skills courses
during the next few years. Mediastinoscopy is not yet obso-
lete, but its role is diminishing and evolving. It is critical
that we as thoracic surgeons understand this and adopt
new technologies to the benefit of our patients.References
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